Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ABBV-383 |
Trade Name | |
Synonyms | TNB-383B|TNB383B|TNB 383B|ABBV383|ABBV 383 |
Drug Descriptions |
ABBV-383 (TNB-383B) is a bispecific antibody that targets alpha CD3 and BCMA, potentially resulting in the activation of T-cells and tumor cell lysis (Journal of Clinical Oncology 2018 36:15_suppl, 8034-8034, PMID: 36029527). |
DrugClasses | CD3 Antibody 99 TNFRSF17 Antibody 20 |
CAS Registry Number | NA |
NCIT ID | C164668 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ABBV-383 | ABBV-383 | 0 | 5 |
ABBV-383 + Daratumumab + Dexamethasone | ABBV-383 Daratumumab Dexamethasone | 0 | 1 |
ABBV-383 + Dexamethasone + Lenalidomide | ABBV-383 Dexamethasone Lenalidomide | 0 | 1 |
ABBV-383 + Dexamethasone + Pomalidomide | ABBV-383 Dexamethasone Pomalidomide | 0 | 1 |
ABBV-383 + Nirogacestat | ABBV-383 Nirogacestat | 0 | 1 |